Health Care Equipment

Artivion

Artivion released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 116.34 M (forecast USD 115.74 M), actual EPS USD 0.0294 (forecast USD 0.0262)

Artivion Reports Q1 2026 Earnings and Cuts Revenue Growth Forecast

Artivion to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 115.78 M, EPS USD 0.0285

Artivion released FY2025 Q4 earnings on February 12 After-Market (EST), actual revenue USD 115.99 M (forecast USD 116.41 M), actual EPS USD 0.0509 (forecast USD 0.08)

Artivion released FY2025 Annual Earnings on February 12 After-Market EST, actual revenue USD 441.33 M (forecast USD 441.76 M), actual EPS USD 0.21 (forecast USD 0.23)

Artivion to Release FY2025 Q4 Earnings on February 12, After-Market EST; Forecast Revenue USD 116.41 M, EPS USD 0.08

Wall Street Zen Downgrades Artivion Rating to Buy

Artivion Inc.'s Senior Vice President Jean F. Holloway Sells Company's Common Stock

Artivion Inc CEO James P. Mackin Sells 30,921 Shares

Artivion Inc. CEO Reports Ordinary Share Disposition

Artivion released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 113.39 M (forecast USD 110.59 M), actual EPS USD 0.13 (forecast USD 0.0171)

Artivion released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 325.34 M, actual EPS USD 0.148

Lake Street Analyst Reiterates Buy Rating on Artivion, Sets Price Target at $45.00

Artivion to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 110.59 M, EPS USD 0.0171

Takkinen Recommends Healthcare Stocks, Citizens JMP Maintains Buy Rating

Artivion Inc signs real estate purchase and sale contracts

Artivion Reports Q2 2025 Earnings with Increased Net Profit Exceeding Expectations

Artivion released FY2025 Semi-Annual earnings on August 8 After-Market EST with actual revenue of USD 211.95 M and EPS of USD 0.0193

Artivion released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 112.97 M (forecast USD 107.95 M), actual EPS USD 0.03 (forecast USD -0.0042)

Artivion to release FY2025 Q2 earnings on August 7 After-Market EST, forecast revenue USD 107.95 M, EPS USD -0.0042

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

BiomX

Micware

Vida Global

MicroAlgo

MetaVia

Tradr 2X Long XNDU Daily ETF

AORT

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System | AORT Stock News

StockTitan

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System | AORT Stock News

Artivion Completes Acquisition of Endospan Ltd. | AORT Stock News

Artivion Completes Acquisition of Endospan Ltd. | AORT Stock News

Artivion shareholders re-elected all nominated directors at the 2026 Annual Meeting, signaling support for current leadership. They also approved executive compensation packages and ratified Ernst & Young as the auditor for 2026. Analyst ratings for AORT stock are mixed, with a Buy rating and a price target of $36.00, while Spark's AI Analyst rates it as Neutral due to improving fundamentals but weak technicals.

Tip Ranks

Artivion Shareholders Back Board, Pay and Auditor Choices

Ademi LLP is investigating potential securities fraud claims against Artivion, Inc. (NYSE: AORT) due to possible inaccuracies in the company's financial statements and business operations. This follows Artivion's acknowledgment of lower international stent sales attributed to supply chain challenges. The investigation is open to shareholders without any cost or obligation.

prnewswire

11:30 ETShareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion (NYSE:AORT) reached a new 52-week low of $19.16 after Citizens JMP downgraded its price target from $53 to $48. The stock last traded at $25.36, down from a previous close of $35.42. Analysts have mixed ratings, with seven maintaining a 'Buy' and one a 'Hold'. Despite a strong Q1 2026 report, including an 18% revenue increase, negative sentiment persists due to valuation concerns and lowered price targets from analysts. Insider selling also contributed to the stock's decline.

Market Beat

Stifel Financial

Morgan Stanley

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Artivion (NYSE:AORT) Sets New 12-Month Low Following Analyst Downgrade

FIGS

HUBS

REAL

UPWK

TNDM

Artivion(AORT) fell 28.26%, with a trading turnover 127.8 Million USD, and a year-to-date fell 44.3%. Figs(FIGS) fell 24.33%, with a trading turnover 132.2 Million USD, and a year-to-date rose 2.4%. CloudFlare(NET) fell 23.62%, with a trading turnover 3.8 Billion USD, and a year-to-date fell 0.5%.

Top Gainers&Losers

Figs

CloudFlare

DXC Tech

Kodiak Robotics

HubSpot

Caris Life Sciences

The RealReal

Upwork

Tandem Diabetes

Top 10 US Stock Losers (5.8)

MRVI

In Friday's trading session, several health care stocks experienced significant movements. AMN Healthcare Services surged 25.6% to $28.2, while Inovio Pharmaceuticals and Maravai LifeSciences rose 25.28% and 23.22%, respectively. Conversely, AIM ImmunoTech saw a sharp decline of 35.1% to $0.36, with Artivion and Sensus Healthcare also falling by 26.6% and 26.53%. The Q1 earnings reports for many of these companies were released yesterday, influencing stock performance.

Artivion(AORT.US)

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System | AORT Stock News

Artivion Completes Acquisition of Endospan Ltd. | AORT Stock News

Artivion Shareholders Back Board, Pay and Auditor Choices

11:30 ETShareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion (NYSE:AORT) Sets New 12-Month Low Following Analyst Downgrade

Top 10 US Stock Losers (5.8)

12 Health Care Stocks Moving In Friday's Intraday Session